For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

Crafting a PET tracer to detect α-synuclein deposits in the brain has been an uphill struggle. Now, scientists led by Hironobu Endo and Makoto Higuchi at the National Institutes for Quantum Science ...

For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...

The revelation that tau aggregates can pass between cells, corrupting their intracellular counterparts, changed how the Alzheimer’s field studies tau pathology. At this year’s AD/PD meeting, held in ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...

In the more than a decade since scientists at Washington University and the Mayo Clinic first proposed the now well-known curves of biomarker change over the course of Alzheimer's disease, researchers ...

Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six ...

Clinical care for Alzheimer’s disease is undergoing a sea change. The latest wave? Eleven years after the first amyloid PET tracer was approved by the U.S. Food and Drug Administration, the scans will ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...